Reunion Neuroscience Investor Relations Material
Latest events
Q3 2023
Reunion Neuroscience
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Reunion Neuroscience Inc
Access all reports
Reunion Neuroscience Inc. is a biotechnology company focused on developing innovative treatments for mental health conditions, with a particular emphasis on psychedelic-inspired therapies. The company’s lead programs are aimed at addressing major depressive disorder and other mental health challenges using novel compounds derived from psychedelics. Reunion Neuroscience seeks to advance clinical research and leverage its proprietary technologies to offer new treatment options for patients where traditional therapies may have limited effectiveness. The company is headquartered in Toronto, Canada, and its shares are listed on the Nasdaq.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
REUN
Country
🇺🇸 United States